Strategic Blueprint LLC Makes New $346,000 Investment in Hinge Health Inc. $HNGE

Strategic Blueprint LLC acquired a new position in Hinge Health Inc. (NYSE:HNGE) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 6,692 shares of the company’s stock, valued at approximately $346,000.

Separately, FNY Investment Advisers LLC bought a new stake in shares of Hinge Health in the 2nd quarter worth about $310,000.

Hinge Health Price Performance

Shares of HNGE opened at $49.52 on Monday. Hinge Health Inc. has a 1-year low of $33.42 and a 1-year high of $62.18. The firm’s 50-day moving average is $54.05.

Hinge Health (NYSE:HNGE) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($13.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.98) by ($8.12). The company had revenue of $139.10 million for the quarter, compared to the consensus estimate of $125.16 million. Hinge Health’s quarterly revenue was up 54.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.96) EPS. Hinge Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HNGE. Citizens Jmp began coverage on shares of Hinge Health in a report on Monday, July 14th. They issued a “strong-buy” rating and a $58.00 target price for the company. Morgan Stanley raised their target price on shares of Hinge Health from $57.00 to $67.00 and gave the stock an “overweight” rating in a report on Tuesday, September 23rd. Citigroup began coverage on shares of Hinge Health in a report on Monday, July 14th. They issued an “outperform” rating for the company. Weiss Ratings restated a “sell (d)” rating on shares of Hinge Health in a report on Saturday. Finally, Canaccord Genuity Group raised their target price on shares of Hinge Health from $52.00 to $61.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.47.

About Hinge Health

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.